Caldera Pharmaceuticals, Inc. Announces Corporate Name Change To XRpro Sciences, Inc.

CAMBRIDGE, Mass., Dec. 4, 2014 /PRNewswire/ -- Caldera Pharmaceuticals, Inc. a provider of a unique platform for drug discovery and development services for transporter and ion channel assays for the pharmaceutical industry, today announced that it is changing its corporate name to XRpro Sciences, Inc., effective immediately.

Richie Cunningham, President and CEO stated, "We are very excited about our corporate name change as it better reflects our business and technology.  We believe the XRpro® platform is well positioned to assist the pharmaceutical industry at a time when margins are being challenged and drug development costs are increasing.  We offer a solution that has the potential to allow our customers to attain information resulting in better selectivity of targets for clinical drug development. We are excited about the accelerated interest we received from both large and specialty pharmaceutical companies for both their secondary screening programs and their high throughput screening (HTS) programs.  XRpro® has the unique ability to perform functional assays in 100% serum and for complicated non-electrogenic co-transporters which we deem to be critical needs of the industry."

He continued, "Brand recognition is a critical component as we continue to accelerate the commercialization of our unique XRpro® drug development technology platform to the pharmaceutical and biotech market."

About XRpro Sciences, Inc.

XRpro Sciences, Inc. provides a unique platform for drug discovery and development services featuring high throughput ion channel assays for the pharmaceutical industry. The Company's proprietary advances in X-ray fluorescence provide measurements that would otherwise be difficult or impossible. XRpro® technology directly measures the activity of a drug target, without the need for costly and artifact-causing chemical dyes or radiolabels. For further information, please visit www.xrpro.com.

Investor Contact:

Aimee Boutcher - [email protected]

Daniel Boutcher - 973 332-0120

This release includes forward-looking statements on the Company's current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict and include statements regarding the potential for our platform, the positioning of the platform in the market and continued acceleration of commercialization of the Company's technology. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from those reflected in the Company's forward-looking statements include, among others, our ability to sell and market our technology and services and the other factors described in the Company's Report on Form 10-K for the year ended December 31, 2013 and any other filings with the SEC. The information in this release is provided only as of the date of this release, and the Company undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/caldera-pharmaceuticals-inc-announces-corporate-name-change-to-xrpro-sciences-inc-300004959.html

SOURCE XRpro Sciences, Inc.

Related Links

http://www.xrpro.com